scholarly journals Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy

2021 ◽  
Vol 12 ◽  
Author(s):  
Shuang-Lu Liao ◽  
Miao Yu ◽  
Zuo-Tao Zhao ◽  
Marcus Maurer

Most chronic spontaneous urticaria (CSU) patients are female, and pregnancy can aggravate the disease activity of patients, but little is known about the efficacy and safety of omalizumab in pregnant CSU patients. We report two pregnant CSU patients treated with omalizumab and review the published information on omalizumab treatment during 11 pregnancies. The outcomes reported on patients with known pregnancies showed they had normal pregnancies and healthy babies as well as complete control of their CSU. The two new cases we reported support the view that omalizumab could be an effective and safe treatment option for pregnant and breastfeeding CSU patients. Further high-quality studies need to be carried out in order to obtain more information on the long-term efficacy and safety of the use of omalizumab during pregnancy in patients with chronic urticaria, including CSU.

Blood ◽  
2017 ◽  
Vol 130 (9) ◽  
pp. 1097-1103 ◽  
Author(s):  
Zhangyuan Kong ◽  
Ping Qin ◽  
Shan Xiao ◽  
Hai Zhou ◽  
Hong Li ◽  
...  

Key Points rhTPO is a potentially effective and safe treatment option for ITP during pregnancy.


2021 ◽  
Vol 6 (3) ◽  
pp. 128-131
Author(s):  
Deeksha Khurana ◽  
Charu Thanvi ◽  
Deepak Raisingani ◽  
Prasad B. Ashwini

Hemisection is sectioning of multi-rooted teeth followed by removal of compromised root along with its associated crown portion and leaving the healthy root (with crown) intact. This treatment option can be considered when caries, resorption, perforation, or periodontal damage is restricted to one root while the other root is relatively healthy. The most critical factor determiningthe long term success in such cases is the appropriate case selection. This case report describes a case of hemisectionof a mandibular molar followed by adequate restoration in a young patient.


Pharmaceutics ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 171
Author(s):  
Beata Sarecka-Hujar ◽  
Beata Szulc-Musioł

Since the teratogenicity of Thalidomide has been proven, herbal products are more commonly used in pregnancy to not only relieve morning sickness but also to fight infections. These products are frequently considered as natural and therefore harmless. However, herbs contain a number of active substances that, when used during pregnancy, can affect the development of the fetus. Often, pregnant women do not consult the usage of herbal medicines with a physician. The access to these products is easy and treatment of certain ailments with the use of herbs is common in many countries. The aim of the present literature review was to discuss available data regarding the efficacy and safety of cranberry, chamomile, Echinacea purpurea, garlic, ginger, Ginkgo biloba, and peppermint, which are used to counteract the most common ailments during pregnancy, i.e., infections and pregnancy-related ailments (e.g., nausea and vomiting, dizziness, and headache). Analysis of available data showed that ginger is one of the most extensively analyzed herbal remedies. The dose of ginger below 1000 mg per day may help to relief hypereremesis gravidarum, and such an amount of ginger did not increase frequency of adverse effects for either woman or developing fetus. Data regarding other herbs are most often heterogeneous and give conflicting results with no clear conclusions. However, all herbal products should be used with a special caution in pregnancy. Further high-quality human studies should be determined to confirm the safe doses of herbal products which could be used by pregnant or breast-feeding women.


2020 ◽  
Vol 71 (1) ◽  
pp. 390-394
Author(s):  
Calin Bogdan Chibelean ◽  
Veronica Ghirca ◽  
Razvan-Cosmin Petca ◽  
Daniel Porav-Hodade ◽  
Ioan Alin Nechifor-Boila ◽  
...  

The aim of this study is to evaluate the efficacy and safety of Uractiv Control as an alternative treatment with no side effects in Overactive Bladder (OAB). We performed a prospective study over a period of 15 months (May 2018- September 2019) in Department of Urology from Targu-Mureș. We included 165 patients diagnosed with OAB wet (129 patients) and dry form (36 patients) which were fully evaluated over a 3-month period of treatment. 48 patients were treated with placebo 1 month and were evaluated by the same parameters like Uractiv Control group. The frequency of micturition during the day and night after the treatment with Uractiv Control was improved compared to placebo group (p=0.0001) and also the loss of urine episodes (p=0.03). Patients did not report any significant side effects of the treatment. Uractiv Control represents a safe treatment option with no side effects and improvement of the storage in OAB.


2016 ◽  
Vol 203 ◽  
pp. 62-68 ◽  
Author(s):  
A. Ringle ◽  
M. Richardson ◽  
F. Juthier ◽  
N. Rousse ◽  
A.S. Polge ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document